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RESUMEN
Introducción: El objetivo del presente estudio fue formular y caracterizar el Sistema Flotante (FRS, siglas 
en Inglés) de Amoxicilina para prolongar el tiempo de residencia gástrica y liberación del fármaco para 
el enfoque efectivo del Helicobacter pylori.
Método: Para el presente estudio se seleccionaron como factores goma guar, Monoestearato de glicerilo 
(GMS), carbonato de calcio. Como reacciones, se seleccionaros el período de congelación (h), el lapso de 
flotación (min), y el porcentaje acumulado de liberación del fármaco (CDR). Para la experimentación se 
seleccionaron el diseño factorial 23 con réplicas.
Resultados: Se observó que la goma guar y el GMS fueron los factores principales que afectaron el perío-
do de congelación y mostraron un efecto sinérgico (positivo). Mientras que la goma guar y el carbonato 
de calcio mostraron un efecto positivo y el GMS mostró un efecto antagónico (negativo) en el lapso de 
flotación. El porcentaje CDR mostró un efecto antagónico en todos los factores. Se emplearon curvas 
de nivel para identificar el diseño del espacio, análisis numéricos posteriores produjeron 12 soluciones 
óptimas en base a la deseabilidad. El FRS mostró un mayor AUCo-t, Cmax, tmaxy t1/2 cuando se comparó 
con la formulación comercial, aproximadamente 2.30 cambios múltiplos y prolongación con liberación 
sostenida por más de 24 h que pudo deberse a una mejor congelación.
Conclusiones: Se puede concluir que el sistema flotante se desarrolló satisfactoriamente por la aplica-
ción del Diseño de Experimentos (DoE) con menores ensayos y utilizando fácilmente los excipientes 
disponibles para una mejor flotación, congelación y suministro constante del fármaco.
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ABSTRACT
Introduction: The aim of the present study was to develop and to characterize the floating raft system 
(FRS) of Amoxicillin to enhance gastric residence time and drug release to target Helicobacter pylori ef-
fectively.
Method: In the present study, guar gum, glyceryl monostearate (GMS), calcium carbonate were selected 
as factors. Gelation duration (h), floating lag time (min), and % Cumulative drug release (CDR) were 
selected as responses. 23 factorial design with replicates was selected for experimentation.
Results: It was observed that guar gum and GMS were the major factors affecting gelation duration, in-
crease in the quantity of both guar gum and GMS increased gelation duration i.e., sustained gelation pe-
riod (24 h). Floating time increased with an increase in the amount of guar gum and calcium carbonate, 
whereas an increase in the quantity of GMS decreased floating time. Guar gum, calcium carbonate, and 
GMS exhibited an antagonistic effect on % CDR. Contour plots were used to identify design space; 
further numerical analysis yielded 12 best solutions based on desirability. FRS exhibited greater AUCo-t, 
Cmax, tmax, and t1/2 when compared to marketed formulation approximately 2.30 folds enhancement and 
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Conclusions: It can be concluded that the floating raft system was 
successfully developed by the Design of experiment (DoE) appli-
cation with fewer trails and by utilizing easily available excipients 
for better floating, gelation, and sustained delivery of the drug.
Keywords: Floating raft system; Helicobacter pylori; factorial De-
sign; Invivo studies
INTRODUCTION
About half a million new cases per year have been record-
ed with gastric and duodenal cancers majorly linked to H. 
Pylori infection (1). The development of the proper floating 
retentive system is essential to eradicate H. Pylori since its 
absorption in the mucous layer is more effective than the 
basolateral membrane (2). Hence Floating Raft System (FRS) 
was selected to improve gelation, duration, and better drug 
release for effectively treating this infection. As of literature 
search, this drug was not developed in the form of FRS. 
Hence we selected this system to improve its availability 
at the target site for the eradication of H. pylori. When FRS 
comes in contact with gastric fluids, a viscous cohesive gel 
is formed, wherein each portion of the liquid swells form-
ing a continuous layer called Raft.
Several dosage forms were formulated among FRS showed 
benefits like ease of manufacturing processes, administra-
tion, and to float faster with better compliance to the pa-
tient (3). The problems of bacterial resistance and side effects 
associated with Amoxicillin could be reduced by formu-
lating gastro retentive FRS, as they provide an appropriate 
prolongation of drug release near the bacterial ecological 
niche (4).
Design of Experiment (DoE) is an essential statistical ap-
proach that can be utilized to optimize and to select com-
patible stable formulation by the screening of variables. 
Adopting this technique minimizes the time where the for-
mulation can be optimized by a few trails, thereby reducing 
the cost of final Amoxicillin product with in-built quality. 
Hence in the present study, the formula was developed and 
optimized by 23 factorial design with replicates.
MÉTHODES
Preparation of the floating raft system
Sixteen formulations (Table 1) were designed as per 23 fac-
torial design (8 formulations+8 replications, Design expert 
software version 11.0) and were developed by the method 
as described below.
Preparing a dispersion medium in which the guar gum 
was dispersed in 90 mL of deionized water along with 
0.25% w/v-sodium citrate and heated at 90ºC. The medi-
um stirred until it appears as a homogenous viscous liquid. 
Later cooled to 40ºC and dispersed Amoxicillin drug in the 
medium and then followed by the addition of 10 mL of cal-
cium carbonate dispersions with stirring. GMS was melted 
to 90ºC and dispersed it into the above drug incorporated 
gum formulation by homogenization using a high-speed 
homogenizer (2) (Figure 1).
Table 1. Formulation table of Amoxicillin floating raft system (Factors & responses)
Formulation
Factor 1










FT Lag time 
(min)
Response 3
% CDR at 24 h
1 3.00 1.00 1.00 20 4 90.2
2 3.00 1.00 1.00 20 4.1 88.4
3 4.00 1.00 1.00 24 2.5 82.4
4 4.00 1.00 1.00 24 2 80.2
5 3.00 1.50 1.00 15 5 84.4
6 3.00 1.50 1.00 15 5.5 80.7
7 4.00 1.50 1.00 24 2.5 85.1
8 4.00 1.50 1.00 24 1.5 90.7
9 3.00 1.00 1.50 24 1.5 95.4
10 3.00 1.00 1.50 24 2 94.7
11 4.00 1.00 1.50 24 1 97.4
12 4.00 1.00 1.50 24 1.2 94.2
13 3.00 1.50 1.50 24 4 87.6
14 3.00 1.50 1.50 24 4 80.7
15 4.00 1.50 1.50 20 3.5 80.2
16 4.00 1.50 1.50 20 3.5 85.1
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Figure 1. Amoxicillin Floating Raft System (FRS) A. Side view B. Top view
Invitro Gelation study
Prepared and collected pH 1.2 dissolution media in vials 
to maintain SGF (stimulated Gastricfluids) condition at 
37±0.5ºC. Add a drop of formulation in each vial and make 
a visual observation on Gelation lag time (time taken to the 
formation of gel) and Gelation duration (time taken to dis-
solve)(5).
Measurement of viscosity
FRS viscosity was measured by Brookfield viscometer by 
changing the angular velocities 10 -100 RPM at 23 ±0.5°C(6).
In-vitro floating study
USP dissolution apparatus II was used. 900 mL of pH 1.2 
dissolution media was prepared to create SGF (Stimulated 
Gastric Fluid) condition. 10 mL of in-situ gel formulation 
was added slowly in each dissolution médium without 
disturbance at 37±0.5°C, and visual observation was made 
on floating lag time (time for the formulation to appear on 
the médium surface) and floating duration (time taken to 
dissolve gel)(2).
In vitro drug release
The study was performed using 0.1N HCl buffer (pH 1.2) and 
maintained at 37±0.5ºC with 50 RPM. 10 ml of gel formulation 
was taken into the watch glass and kept in the dissolution medi-
um. The sample was collected at each interval time and replaced 
the same amount of buffer médium, which was prewarmed and 
maintained at 37°±5C. Spectrophotometrically measured at 210 
nm. All dissolutions were performed in triplicate.(2)
In vivo Pharmacokinetic studies
A total of 4 healthy rabbits were randomly divided into two 
groups, and each group consisting of two animals. Group-I: 
Administration of marketed formulation (EDMOX). 
Group-II: Administration of optimized FRS. After a single 
oral administration, 0.25ml blood sample was collected 
from either left or right marginal ear vein using a 3ml nee-
dle at 0, 0.5, 1, 1.5, 3, 4.5, 6, 12 and 24h. Blood samples were 
analyzed further by HPLC technique for measurement of 
pharmacokinetic parameters like AUCo-t, Cmax, tmax, and t1/2. 
The measurements were assessed at p<0.05 (7,8).
RESULTS AND DISCUSSION
In the present study, guar gum, calcium carbonate, and 
GMS were selected as factors and gelation time duration (h), 
floating lag time, and % cumulative drug release (%CDR) 
were selected as responses. These were selected based on 
the literature survey. After selection, preliminary studies 
were conducted, and the concentrations were fixed, fol-
lowed by experimentation using the Design of experiments 
(Factorial design, Design expert software version 11). The 
study was conducted at 2 levels 3 factors with replications 
(8) (8+8 total of 16 experiments). It was observed that guar 
gum and GMS were the significant factors affecting gela-
tion duration, increase in the quantity of both guar gum, 
and GMS increased gelation duration i.e., sustained gela-
tion period (24 h). Floating time increased with an increase 
in the amount of guar gum and calcium carbonate, whereas 
an increase in the quantity of GMS decreased floating time. 
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An increase in the amount of guar gum, calcium carbonate, 
and GMS decreased % CDR i.e., sustained the release of the 
drug for 24 h (equation 1, 2, 3). All the desired factors exhib-
ited probability at <0.05, indicating significance at that level 
(Table 2). In all the cases, the predicted R2 is closer to ad-
justed R2, and adequate precisión values were greater than 
4 and indicated adequate signal. Hence it was used to nav-
igate the design space. A significant factor that affects the 
formulation was identified by Pareto charts and by cooks 
distance. Pareto chart is a useful tool to identify statistical-
ly significant effects by t-value limits; the effects above the 
t-value indicated significant factors. The predicted vs. actu-
al values plot revealed that the experimental values were in 
close agreement with the predicted values (Figure 2).
Gelation duration = -66.00000 + 23.50000 *Guargum 
+64.0000 GMS -170000 Guargum *GMS  --- 1
Floating Lag time = +1.22500 + 0.075000 *Guar gum 
+7.35000* Calcium carbonate -1.60000*GMS-1.30000* Guar-
gum* Calcium carbonate    --- 2
% CDR at 12h = +418.50000-114.60000 *Guar gum -264.20000 
*Calcium carbonate -211.60000 *GMS + 89.10000 *Guar gum 
*Calcium carbonate +79.90000*Guar gum*GMS +170.60000 
Calcium carbonate *GMS-62.40000*guar gum *calcium car-
bonate* GMS     --- 3




df Mean square F Value p-value
Model 112.75 3 37.58 11.00 0.0009 significant
A-Guar gum 20.25 1 20.25 5.93 0.0315
C-GMS 20.25 1 20.25 5.93 0.0315
AC 72.25 1 72.25 21.15 0.0006
Residual 41.00 12 3.42
Lack of fit 41.00 4 10.25
Pure error 0.000 8 0.000
Cor Total 153.75 15
Contour plots (Figure 3) were used to identify design 
space; further numerical analysis yielded 12 best solutions 
based on desirability. To achieve desired criteria, i.e., gela-
tion time closer to 24 h, floating lag time 1-2 min, and % 
CDR greater than 95%, the factors can be varied at 3.79-4.00 
% of guar gum, calcium carbonate and GMS at 1 and 1.5% 
respectively with the desirability of 0.899-0.902. Calcium 
carbonate generates gas, which is obtained from calcium. 
When the formulation comes in contact with stomach acid-
ic pH, carbon dioxide gas is evolved. It shows in situ release 
along with floating properties because of entrapping of gel 
network in the formulation and enhance gel floating on the 
surface of the dissolution medium (Invitro) or the stomach 
(Invivo). These Ca2+ions are responsible for gelation through 
a cross-linking polymer chain. Lipid emulsification ame-
liorated the FRS characteristics. Incorporation of GMS en-
hanced the gelation efficiency with an increased Gelation 
period from a few hours to greater than 24h. The AUC 0-t, 
of the marketed formulation, was found to be 42.27 µg.h/
ml. The increase in AUC0-t was observed in the FRS (test) 
formulation, which was around 68.42 µg.h/ml. This indi-
cated the drug availability for a long duration. The mean 
peak plasma concentration of test formulationCmax6.97 µg/
ml gradually reached in 4 h. In the case of marketed formu-
lation (R), the Cmax was 3.02 µg/ml gradually reached in 3 h. 
The Cmax of the marketed formulation was less when com-
pared with the test formulation. The increase in tmax indi-
cated drug availability for a prolonged period. The plasma 
elimination half-life (t1/2) of the marketed formulation was 
4.72 h, and the FRS (T) formulation was 5.98 h, which were 
significantly different. The overall Cmax, tmax, AUCo-t, and t1/2 
were completely different between both the test and mar-
keted formulations (Fig 4). Therefore the prepared formula-
tions released the drug for a prolonged period essential for 
the effective eradication of H. pylori infection.
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Figure 2. Diagnostic plots A. Half-Normal Plot B. Pareto chart C. Predicted Vs. Actual D. Cooks Distance E. Box-cox plot for Power 
transforms
Figure 3. Contour plots under Design space
Figure 4. Mean plasma concentration-time profiles after oral administration of FRS (test) and marketed formulations; Each point repre-
sents mean ± SE (n=4, at p<0.05).
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CONCLUSION
Amoxicillin FRS was successfully developed and optimized 
by factorial Design with replicates to enhance gastric resi-
dence time and drug release to effectively target Helicobacter 
pylori. It can be concluded that the floating raft system was 
successfully developed by the Design of experiment (DoE) 
application with fewer trails & by utilizing easily available 
excipients for better floating, gelation, and sustained deliv-
ery of the drug. Invivo studies exhibited better pharmacoki-
netic parameters in FRS (test formulation) than marketed 
formulation that proved extended and prolonged release 
of drug at the required site for treating Helicobacter pylori.
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